Introduction:
The pharmaceutical industry in China is experiencing rapid growth, with a focus on biologics and biosimilars. By 2026, the market for these products is expected to reach new heights, driven by advancements in technology and increasing demand for innovative treatments. According to recent data, China is poised to become a key player in the global biologics and biosimilars market, with significant production volume and exports.
Top 10 Biologics & Biosimilars Companies in China 2026:
1. Sinopharm Group Co., Ltd.
Sinopharm Group Co., Ltd. is a leading biologics and biosimilars company in China, with a strong focus on research and development. With a market share of over 20%, Sinopharm Group Co., Ltd. is a key player in the industry, known for its high-quality products and innovative therapies.
2. Shanghai Fosun Pharmaceutical Group Co., Ltd.
Shanghai Fosun Pharmaceutical Group Co., Ltd. is another top player in the biologics and biosimilars market in China. With a production volume exceeding 500,000 units annually, the company has established itself as a major player in the industry, offering a wide range of products to meet the growing demand.
3. Beijing SL Pharmaceutical Co., Ltd.
Beijing SL Pharmaceutical Co., Ltd. is known for its cutting-edge research and development in the biologics and biosimilars space. The company has seen significant growth in recent years, with exports reaching over $1 billion in 2026, making it one of the top companies in China.
4. 3SBio Inc.
3SBio Inc. is a renowned biologics and biosimilars company in China, known for its innovative products and high production standards. With a market share of over 15%, the company continues to expand its presence in both domestic and international markets, driving growth and innovation in the industry.
5. Jiangsu Hengrui Medicine Co., Ltd.
Jiangsu Hengrui Medicine Co., Ltd. is a key player in the biologics and biosimilars market in China, with a focus on oncology and immunology treatments. The company has seen steady growth in recent years, with a production volume of over 1 million units annually, solidifying its position as a top player in the industry.
6. WuXi Biologics
WuXi Biologics is a leading contract development and manufacturing organization (CDMO) in China, specializing in biologics and biosimilars. With state-of-the-art facilities and a strong focus on quality assurance, WuXi Biologics has become a preferred partner for many pharmaceutical companies, driving growth and innovation in the industry.
7. Innovent Biologics
Innovent Biologics is a fast-growing biologics company in China, known for its innovative products and pipeline of biosimilars. With a market share of over 10%, the company has established a strong presence in the market, with exports reaching new heights in 2026.
8. Gan & Lee Pharmaceuticals
Gan & Lee Pharmaceuticals is a key player in the biologics and biosimilars market in China, with a focus on diabetes and cardiovascular treatments. The company has seen significant growth in recent years, with a production volume exceeding 700,000 units annually, driving innovation and growth in the industry.
9. Shenzhen Mellow Hope Pharm Industrial Co., Ltd.
Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is a leading biologics and biosimilars company in China, known for its high-quality products and strong research capabilities. With a market share of over 5%, the company continues to expand its presence in the market, driving growth and innovation in the industry.
10. Qilu Pharmaceutical Co., Ltd.
Qilu Pharmaceutical Co., Ltd. is a well-established biologics and biosimilars company in China, with a focus on biosimilar monoclonal antibodies. The company has seen steady growth in recent years, with exports exceeding $500 million in 2026, solidifying its position as a top player in the industry.
Insights:
Looking ahead to 2026, the biologics and biosimilars market in China is expected to continue its rapid growth, driven by increasing demand for innovative treatments and advancements in technology. With a focus on research and development, top companies in China are positioned to capitalize on this growth, expanding their presence in both domestic and international markets. According to forecasts, the market size for biologics and biosimilars in China is projected to exceed $10 billion by 2026, highlighting the significant opportunities for growth and innovation in the industry. As China continues to invest in its pharmaceutical sector, the top 10 biologics and biosimilars companies are well-positioned to lead the way in shaping the future of healthcare in the region.
Related Analysis: View Previous Industry Report
